PLAUR and COVID-19: A double‐blinded, randomised, controlled, phase 3 trial at 37 study sites in Greece and Italy (NCT04680949) recruited 594 patients with moderate or severe COVID‐19 who were at risk of progressing to respiratory failure based on soluble urokinase plasminogen activator receptor (a biomarker that predicts the development of severe COVID‐19) serum levels of ≥6 ng ml−1.